AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30852728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received two oral HIVST kits only.
Trial: 9173422
Drug: Theophylline (Uniphyllin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (Uniphyllin; 600 mg nocte orally)
Trial: 28736545
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy
Trial: 7564037
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of buprenorphine (intermittent injection before awakening from anesthesia)
Trial: 7564037
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of buprenorphine (continuous injection)
Trial: 6113683
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg l-hyoscyamine
Trial: 373073
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg trimipramine
Trial: 1782305
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine
Trial: 21435854
Drug: Budesonide/formoterol (Symbicort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (Symbicort® Turbuhaler® maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2
Trial: 21435854
Drug: Budesonide/formoterol (Symbicort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (Symbicort® Turbuhaler® maintenance and reliever therapy (Symbicort SMART®), 2 × 2
Trial: 11324212
Drug: Implants loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants loaded with an overdenture connected with ball abutments after 3 months (control group)
Trial: 27400374
Drug: Celecoxib treatment
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib treatment
Trial: 10749783
Drug: Endotoxin (lowest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin (lowest dose)
Trial: 10749783
Drug: Endotoxin (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin (highest dose)
Trial: 1305043
Drug: Ukrain (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain (2.5 to 25 mg per injection, intramuscularly or intravenously, every 1-5 days)
Trial: 1305043
Drug: Ukrain (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain (various dosing schedules and intervals)
Trial: 3977491
Drug: 3 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 micrograms of heat-inactivated hepatitis B vaccine
Trial: 3977491
Drug: 27 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27 micrograms of heat-inactivated hepatitis B vaccine
Trial: 23197572
Drug: Tadalafil (a
RxNorm normalized name: TADALAFIL (ADCIRCA) 20MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (a phosphodiesterase 5A inhibitor), single dose
Trial: 18091705
Drug: Interstitial magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interstitial magnetic resonance lymphography (MRL) using subcutaneous gadobutrol (5 mL: 4.5 mL Gadobutrol + 0.5 mL lidocaine hydrochloride)
Trial: 18091705
Drug: X-ray direct
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X-ray direct lymphography (lipiodol administered after 7 days in 3 patients)
Trial: 2799034
Drug: Pankreon 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pankreon 700 (17 tablets, 11.9 g pancreatin, 476,000 UFIP lipase)
Trial: 2799034
Drug: Control (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (first week without treatment)
Trial: 23427838
Drug: Hypnotic tape
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic tape intervention
Trial: 9104618
Drug: Endonasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endonasal administration of an IgA enriched preparation
Trial: 27870712
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 160 mg/d
Trial: 8478668
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 480 mg/d
Trial: 8478668
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 1280 mg/d
Trial: 9480997
Drug: both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both treatments
Trial: 24763156
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy intervention
Trial: 12198052
Drug: Target-Controlled Infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-Controlled Infusion (TCI) of propofol (plasma target concentration, 2.5-3.5 micro g/mL; n = 20)
Trial: 12198052
Drug: Manually-Controlled Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manually-Controlled Infusion (MCI) of propofol (3.0-4.0 mg.kg(‐1).h(‐1); n = 20)
Trial: 2031196
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose tamoxifen, 150 mg/m2 orally daily for 6 months, then 50 mg/m2 until tumor progression (arm B)
Trial: 16435471
Drug: ranitidine (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (320 mg/day)
Trial: 1459517
Drug: cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine (800 mg/day)
Trial: 2944380
Drug: ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (150 mg twice daily)
Trial: 28167545
Drug: MRX-I single
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRX-I single ascending doses under fasting or fed condition
Trial: 28167545
Drug: MRX-I 800
RxNorm normalized name: MRX-I
DrugBank: MRX-I (DB12796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRX-I 800 mg every 12 hours for 14 days
Trial: 28167545
Drug: MRX-I 800
RxNorm normalized name: MRX-I
DrugBank: MRX-I (DB12796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRX-I 800 mg every 12 hours for 28 days
Trial: 21255957
Drug: RVX-208 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVX-208 (50, 100, or 150 mg twice daily for 12 weeks)
Trial: 19593886
Drug: Scheduled analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled analgesia with lornoxicam (8 mg preoperatively, 8 mg after 6-8 hours, and 8 mg every 8 hours for 48 hours postoperatively)
Trial: 11385269
Drug: rizatriptan 10-mg
RxNorm normalized name: rizatriptan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rizatriptan 10-mg
Trial: 11576197
Drug: sumatriptan 50-mg
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumatriptan 50-mg tablet
Trial: 2874783
Drug: Epinephrine added
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine added to betaxolol treatment
Trial: 2874783
Drug: Epinephrine added
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine added to timolol treatment
Trial: 29853453
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered for 24 weeks.
Trial: 26711799
Drug: Conventional with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional with VT therapy ≥170 (Treatment arm A)
Trial: 25330017
Drug: Ongoing buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing buprenorphine maintenance therapy
Trial: 25330017
Drug: Buprenorphine taper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine taper
Trial: 23735180
Drug: Reference sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reference sirolimus tablets
Trial: 20619475
Drug: 360 microg
RxNorm normalized name: Interferon alfa-2a (as peginterferon alfa-2a) 360 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 microg PEG‐IFNalpha‐2a weekly with RBV 1000‐1200 mg/day for 12 weeks followed by 36 weeks of 180 microg PEG‐IFNalpha‐2a weekly plus RBV 1000‐1200 mg/day
Trial: 20619475
Drug: 180 microg
RxNorm normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 microg PEG‐IFNalpha‐2a weekly with RBV 1000‐1200 mg/day for 12 weeks followed by 36 weeks of 180 microg PEG‐IFNalpha‐2a weekly plus RBV 1000‐1200 mg/day
Trial: 8852414
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B subunit‐killed whole cell (BS‐WC) vaccine
Trial: 8852414
Drug: Killed whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole cell‐only (WC) vaccine
Trial: 1737542
Drug: Subcutaneous intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous intensive insulin therapy (SC)
Trial: 29777975
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + chemotherapy (BEV)
Trial: 26914135
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg pregabalin per os (Group P75)
Trial: 26914135
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pregabalin per os (Group P150)
Trial: 26914135
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg pregabalin per os (Group P300)
Trial: 24552826
Drug: Anabolic steroids
RxNorm normalized name: ANABOLIC STEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabolic steroids combined with a daily high-protein, high-calorie diet
Trial: 10581593
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol (insulin clamp)
Trial: 2912119
Drug: 0.5% balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% balanced salt solution (placebo)
Trial: 23413998
Drug: Fluoxetine co-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine co-administration with clopidogrel
Trial: 15182397
Drug: Phenolic-rich dessert
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenolic-rich dessert (200 g daily for 2 weeks)
Trial: 31233373
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy using a sports bra of compression type for 9 months
Trial: 25319385
Drug: Inappropriate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate antibiotic therapy
Trial: 18052559
Drug: Desvenlafaxine (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (100-200 mg/day)
Trial: 17465457
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EUS and MMP-9
Trial: 15163163
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy Scale‐General (FACT‐G)
Trial: 11310450
Drug: Freedom from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freedom from treatment failure (FFTF) for all patients with secondary NHL
Trial: 11310450
Drug: Freedom from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freedom from treatment failure (FFTF) for patients with diffuse large-cell lymphoma
Trial: 8198080
Drug: FR‐3 appliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FR‐3 appliance therapy
Trial: 31124042
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (2.5 mg or 100,000 IU)
Trial: 24047486
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical therapy (CMT)
Trial: 24928796
Drug: Oxybutynin 2.5
RxNorm normalized name: oxyBUTYnin 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 2.5 mg
Trial: 14671905
Drug: Isoflurane and
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane and intravenous bolus injections of fentanyl with epidural anesthesia by morphine at lumbar level
Trial: 9215817
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 40 mg four times daily
Trial: 9367070
Drug: Oral retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral retinol (25,000 units)
Trial: 9367070
Drug: Isotretinoin (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (5-10 mg)
Trial: 31584684
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (30% decrease in daily rates) for MRSA bacteremia
Trial: 31584684
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30% decrease in daily rates) for MRSA bacteremia
Trial: 31584684
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (30% decrease in daily rates) for CAUTI
Trial: 31584684
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30% decrease in daily rates) for CAUTI
Trial: 31584684
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (30% decrease in daily rates) for CLABSI
Trial: 31584684
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30% decrease in daily rates) for CLABSI
Trial: 31584684
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (30% decrease in daily rates) for CDI
Trial: 31584684
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30% decrease in daily rates) for CDI
Trial: 29972861
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl and No fentanyl
Trial: 15705120
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR 75 mg
Trial: 15705120
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR 150 mg
Trial: 12011124
Drug: ACVBP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACVBP chemotherapy
Trial: 16432076
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT)
Trial: 7672654
Drug: Nafarelin acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin acetate, administered pre-operatively for three months
Trial: 31553834
Drug: Vedolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (300 mg infusion on day 1 and at weeks 2, 6, 14, 22, 30, 38, and 46)
Trial: 31553834
Drug: Vedolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (300 mg infusion)
Trial: 31553834
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg subcutaneous injection at week 1, 80 mg at week 2, and 40 mg every 2 weeks thereafter)
Trial: 31553834
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg subcutaneous injection)
Trial: 28915826
Drug: HuoXueSanFeng acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuoXueSanFeng acupuncture combined with one antihypertensive medication
Trial: 11141029
Drug: Presurgical infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical infant orthopedic treatment (PIO) during the first year of life
Trial: 22538118
Drug: Ginger (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (2 g ginger powder in hot water)
Trial: 2104627
Drug: Enalapril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (ACE inhibitor) for 30 days
Trial: 211983
Drug: Fluphenazine enanthate
RxNorm normalized name: Fluphenazine Enanthate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine enanthate low-dose (0.25 ml) with family therapy
Trial: 19223643
Drug: IDX899 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX899 50 mg capsule
Trial: 19223643
Drug: IDX899 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX899 200 mg capsule
Trial: 19223643
Drug: IDX899 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX899 800 mg once daily (QD)
Trial: 19223643
Drug: IDX899 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX899 400 mg twice daily (BID)
Trial: 6476557
Drug: New cardiopulmonary-cerebral
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cardiopulmonary-cerebral resuscitation therapies
Trial: 24588932
Drug: Multispecies probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies probiotic (6 different probiotic strains; 10^9 cfu/g) for 6 weeks
Trial: 11020745
Drug: Epinephrine test
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine test dose
Trial: 11020745
Drug: Isoproterenol test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol test dose
Trial: 1972927
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg astemizole
Trial: 1510286
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg astemizole
Trial: 6426893
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous fluids (carbohydrates and amino acids)
Trial: 31061014
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (psychosocial intervention administered by speech and language therapists)
Trial: 16882684
Drug: Intranasal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal lidocaine 8% spray
Trial: 16882684
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo spray
Trial: 11512528
Drug: clarithromycin MR
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin MR 500 mg once daily
Trial: 8112370
Drug: Entacapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (200 mg oral dose)
Trial: 18661769
Drug: Acetaminophen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (10 mg/kg) along with DTP vaccine
Trial: 18661769
Drug: Acetaminophen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (10 mg/kg) 2 hours after vaccination
Trial: 18661769
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (acetaminophen after febrile reactions or irritability)
Trial: 9845865
Drug: Outpatient drug-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient drug-free programs
Trial: 8591712
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg daily for 12 weeks)
Trial: 2612542
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam at 0.15 mg.kg‐1
Trial: 2612542
Drug: Rectal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal midazolam at 0.15 mg.kg‐1
Trial: 2612542
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam at 1 mg.kg‐1
Trial: 1037281
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mefexamide
Trial: 1037281
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg mefexamide